Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.43 |
| ▸ | XIAP | P98170 | 3/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870911 | 0.82 | NAAA (0.46) | NAAAXIAPSENP1PARP1CTSL | |
| SCHEMBL5114897 | 0.81 | NAAA (0.44) | NAAASENP1PARP1CTSLCTSB | |
| SCHEMBL4797980 | 0.81 | PYGL (0.47) | NAAAXIAPPARP1CTSLCTSB | |
| SCHEMBL4871485 | 0.78 | NAAA (0.50) | NAAACTSLEPHX1ALDH1A1 | |
| SCHEMBL4870965 | 0.78 | NPY1R (0.43) | XIAPPYGLALDH1A1SMN1; SMN2 | |
| SCHEMBL6216047 | 0.78 | SMN1; SMN2 (0.59) | NAAAPARP1CTSLCTSBPREP | |
| SCHEMBL3932072 | 0.78 | SMN1; SMN2 (0.59) | NAAAPARP1CTSLCTSBPREP | |
| SCHEMBL3932081 | 0.78 | SMN1; SMN2 (0.59) | NAAAPARP1CTSLCTSBPREP | |
| SCHEMBL4870896 | 0.77 | AADAT (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL7420876 | 0.72 | CA1 (0.49) | NAAAPARP1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368458-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-06 | — | — | US | disclosed |
| US-7314882-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314882-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| WO-2006076597-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155126-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | NAAA 240/4885XIAP 4547/4885SENP1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.